|
|
|
|
|
|
|
|
|
|
|
|
|
12.01.26 - 14:36
|
Johnson & Johnson Aktie: Comeback für Healthcare 2026? (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Sanford C. Bernstein:
Bernstein-Analyst Lee Hambright habe das Kursziel für die Aktie von Johnson & Johnson (J&J) (ISIN: US4781601046, WKN: 853260, Ticker-Symbol: JNJ, NYSE-Symbol: JNJ) von 193 auf 208 USD angehoben, das "market perform"-Rating aber beibehalten. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.01.26 - 22:15
|
GenNx360 Capital Partners Portfolio Company Nutra-Med Packaging Appoints Hany Salama as Chief Executive Officer (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--GenNx360 Capital Partners (“GenNx360”), a New York City-based private equity firm investing in middle-market industrial and business services companies, today announced the appointment of Hany Salama as Chief Executive Officer of its portfolio company, Nutra-Med Packaging (“Nutra-Med” or the “Company”), one of the leading contract development and manufacturing organizations serving the health, wellness, and pharmaceutical sectors. Mr. Salama succeeds Kunal Gupta, effective January 12, 2026.
Mr. Salama brings more than twenty years of global leadership experience across healthcare, biopharma, consumer health, and life sciences. He has held senior operational and commercial roles at some of the world's most respected organizations, including Johnson & Johnson, Merck, Roche, and BASF. At Johnson & Johnson, he led end-to-end supply chain and manufacturing operations for major consumer brands across complex, highly regulated environments. Most recently, as Senior Vice Pr...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
